UiPath Inc. (NYSE:PATH – Get Rating) CAO Hitesh Ramani sold 2,100 shares of the business's stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $14.45, for a total transaction of $30,345.00. Following the sale, the chief accounting officer now directly owns 438,452 shares in the company, valued at approximately $6,335,631.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Hitesh Ramani also recently made the following trade(s):

Get UiPath alerts:

• On Wednesday, November 16th, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $13.15, for a total transaction of $27,615.00.
• On Wednesday, November 9th, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $11.00, for a total transaction of $23,100.00.
• On Wednesday, November 2nd, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $12.29, for a total transaction of $25,809.00.
• On Wednesday, October 26th, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $12.02, for a total transaction of $25,242.00.
• On Wednesday, October 19th, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $12.10, for a total transaction of $25,410.00.
• On Wednesday, October 12th, Hitesh Ramani sold 2,100 shares of UiPath stock. The stock was sold at an average price of $11.88, for a total transaction of $24,948.00.

UiPath Stock Up 1.0 %

Shares of PATH stock opened at $12.56 on Thursday. UiPath Inc. has a 12 month low of $10.40 and a 12 month high of $48.68. The company has a 50 day simple moving average of $12.27 and a two-hundred day simple moving average of $16.03.

UiPath (NYSE:PATH – Get Rating) last announced its earnings results on Thursday, December 1st. The healthcare company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.09. UiPath had a negative net margin of 34.99% and a negative return on equity of 17.19%. The business had revenue of $262.74 million during the quarter, compared to analysts' expectations of $248.07 million. On average, research analysts expect that UiPath Inc. will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Barclays downgraded shares of UiPath from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $17.00 to $15.00 in a research note on Tuesday, October 18th. Bank of America dropped their target price on shares of UiPath from $20.00 to $18.00 in a research note on Wednesday, September 28th. Canaccord Genuity Group dropped their target price on shares of UiPath from $15.00 to $14.00 and set a "hold" rating on the stock in a research note on Friday, September 30th. Oppenheimer downgraded shares of UiPath from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 3rd. Finally, Morgan Stanley downgraded shares of UiPath from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $32.00 to $15.00 in a research report on Wednesday, September 7th. Nine research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $22.23.

Institutional Trading of UiPath

A number of hedge funds and other institutional investors have recently modified their holdings of PATH. Envestnet Asset Management Inc. increased its stake in shares of UiPath by 30.1% in the first quarter. Envestnet Asset Management Inc. now owns 243,796 shares of the healthcare company's stock worth $5,264,000 after purchasing an additional 56,476 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of UiPath by 4.3% in the first quarter. Commonwealth Equity Services LLC now owns 51,485 shares of the healthcare company's stock worth $1,111,000 after purchasing an additional 2,100 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in shares of UiPath in the first quarter worth $27,000. California Public Employees Retirement System purchased a new stake in shares of UiPath in the first quarter worth $4,888,000. Finally, Steel Peak Wealth Management LLC increased its stake in shares of UiPath by 116.5% in the first quarter. Steel Peak Wealth Management LLC now owns 41,139 shares of the healthcare company's stock worth $889,000 after purchasing an additional 22,138 shares in the last quarter. 51.35% of the stock is owned by hedge funds and other institutional investors.

About UiPath

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Read More

• Get a free copy of the StockNews.com research report on UiPath (PATH)
• Why You Should Avoid Carvana Even if it Avoids Bankruptcy
• Are Investors Hearing The End Of Spotify's Downtrend?
• The Question of a Fed Pivot Isn't If, It's When, Here's Why
• Top 10 Searched Stocks on MarketBeat All-Access
• 3 Dividend Kings With Royally Good Upside

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.